Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss
In this feasibility study, weekly semaglutide treatment was associated with improvement in self-rated overall QOL and reductions in BMI, HbA1c and blood pressure at up to 6 months follow-up. Even in patients who discontinued treatment before 6 months, initial benefits of weight reduction and improved QOL were still demonstrated. Further evaluation, including health economic assessment and longer-term follow up, may support the expanded use of GLP-1 agonists in improving the cardiometabolic profile and longitudinal health outcomes in individuals with SMI.
Authors
- Onagh Boyle
- Joseph Ingram
- Richard I. G. Holt (ORCID: https://orcid.org/0000-0001-8911-6744)
- Akheel A. Syed (ORCID: https://orcid.org/0000-0001-8696-7121)
- Joseph Firth (ORCID: https://orcid.org/0000-0002-0618-2752)
- Gavin P. Reynolds (ORCID: https://orcid.org/0000-0001-9026-7726)
- Damien Longson (ORCID: https://orcid.org/0000-0002-3072-1023)
- Marc D. Binder (ORCID: https://orcid.org/0000-0003-4255-5920)
- Mike Stedman (ORCID: https://orcid.org/0000-0002-0491-7823)
- Donal O’Shea (ORCID: https://orcid.org/0000-0002-1408-5274)
- Adrian Hugh Heald (ORCID: https://orcid.org/0000-0002-9537-4050)
- Chris Daly
- Isabel Nash
Institutions
- Allen Institute for Brain Science (US)
- Greater Manchester Mental Health NHS Foundation Trust (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- Salford Royal Hospital (GB)
- St. Vincent's University Hospital (IE)
- VIB-KU Leuven Center for Brain & Disease Research (BE)
- University of Southampton (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1007/s12325-025-03261-0
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88